Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Roswell Park Cancer Institute: Clinical Trials & FDA Approval Profile

Roswell Park Cancer Institute (Global / Institutional) sponsors 51 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 27 active protocols (21 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)33.3%
Median Closed Enrollment vs National (145 pts)15 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Roswell Park Cancer Institute
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)51
Active Pipeline (Recruiting Now)27 (21)
Completed vs Stopped Early7 / 17 (33.3%)
Median Closed Actual Enrollment15 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Roswell Park Cancer Institute
Hospital Research SiteLocationShared Protocols
Roswell Park Comprehensive Cancer CenterBuffalo, NY51
Moffitt Cancer CenterTampa, FL2
Cleveland ClinicCleveland, OH2

Explore interactive annual charts and M&A subsidiary rollups in the Roswell Park Cancer Institute Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI